Physician profile
Andre A Kaplan
NPI 1073519294
$572.48
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2022: $184 · 2023: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $193.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.33 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.81 | 2022 | |
| Travere Therapeutics, INC. | $61.97 | 2022 | |
| Akebia Therapeutics INC | $53.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.